Top Markets
Coin of the day
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Ранг среди акций #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Цена акции
$8.74
Последняя синхронизация: 2026-08-28
Рыночная капитализация
$699.74M
Изменение (1 день)
-4.85%
Изменение (1 год)
-2.29%
Страна
US
Торговля BridgeBio Oncology Therapeutics Inc. (BBOT)

Категория

История дивидендной доходности для BridgeBio Oncology Therapeutics Inc. (BBOT)
Дивидендная доходность (TTM) компании BridgeBio Oncology Therapeutics Inc. (тикер: BBOT) на 2026 составляет: 0
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании BridgeBio Oncology Therapeutics Inc. (BBOT) с 2026 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
Недостаточно данных для указанных дат.
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH